李欣,赵立子,黄民
LI Xin,ZHAO Li-zi,HUANG Min (Institute of Clinical Pharmacology

• 1:中山大学临床药理研究所
• 2:中山大学临床药理研究所
• 3:中山大学临床药理研究所 广州510080
• 4:广州510080

摘要(Abstract)：

通过查阅有关书籍和近年国内外的文献资料,回顾治疗药物监测(TDM)的发展与现状,介绍目前进行TDM的药物种类和常用技术方法,展望遗传药理学在个体化用药中的应用前景。未来的治疗药物监测模式是传统模式和药物遗传学监测相结合,进一步完善个体给药方案的制定。
After review the development and situation of TDM,we describe the variety of drugs which need TDM and populat monitoring methods,also prospect the foreground of pharmacogenetics in the individualized medication.The mode of TDM in the future is the combination of traditional methods and pharmacogenetics.

关键词(KeyWords)： 治疗药物监测;色谱法;免疫分析法;遗传药理学
therapeutic drug monitoring;chromatography;pharmacogenetics;immunoassay

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李欣,赵立子,黄民
LI Xin,ZHAO Li-zi,HUANG Min (Institute of Clinical Pharmacology

参考文献(References)：

• [1]W alson PD.Therapeutic drug mon itoring in spec ial popu la-tions[J].C linc Chem,1998,44(2):415-9.
• [2]凌树森.治疗药物监测新理论与新方法[M].北京:中国医药科技出版社,2002:8.
• [3]Johannessen SI,Battino D,Berry D J,B ialerM,Kram erG,Tom son T,Patsalos PN.Therapeutic drug mon itoring of thenewer antiep ileptic drugs[J].Ther D rug Mon it,2003,25(3):347-63.
• [4]H iemke C,D ragicevic A,G runder G,Hatter S,Sachse J,Vernaleken I,Mu ller M J.Therapeutic mon itoring of newantipsychotic drugs[J].Ther D rug Mon it,2004,26(2):156-60.
• [5]Bengtsson F.Therapeutic drug mon itoring of psychotrop icdrugs.TDM"nouveau"[J].Ther D rug Mon it,2004,26(2):145-51.
• [6]Eap CB,S irot EJ,Baum ann P.Therapeutic mon itoring ofantidepressants in the era of pharm acogenetics stud ies[J].Ther D rugMon it,2004,26(2):152-5.
• [7]Schou M.Forty years of lith ium treatm ent[J].Arch GenPsych,1997,54:9-13.
• [8]Fraaij PL,Rakhm an ina N,Burger DM,et al.Therapeuticdrug mon itoring in ch ildren w ith H IV/AIDS[J].Ther D rugMon it,2004,26(2):122-6.
• [9]Ak inobu Ham ada.Developm ent of an Ind ividualized Thera-py for Estab lish ing the Optim al Dosage by the Pharm acok i-netics Profiles of Anticancer Agents[J].The Pharm aceuti-cal Soc iety of Japan,2005,125(8):631-7
• [10]Donnelly JG.Pharm acogenetics in cancer chemotherapy:balanc ing toxic ity and response[J].Ther D rug Mon it,2004,26(2):231-5.
• [11]Erlichm an C,Sold in SJ,Th iessen JJ,et al.D isposition oftotal and free c isp latin on two consecutive treatm ent cyc lesin patients w ith ovarian cancer[J].Cancer ChemotherPharm acol,1987,19(1):75-9.
• [12]Holt DW,Johnston A.Mon itoring immunosuppressivedrugs:has it a future?[J]Ther D rug Mon it,2004,26(3):244-7.
• [13]Jorga A,Johnston A,Holt DW.Patient m anagem ent bycyc losporine C2 mon itoring[J].Transp lantation,2004,77(2):323-4.
• [14]Holt DW.Mon itoring mycophenolic ac id[J].Ann C linB iochem,2002,39(Pt 3):173-83
• [15]Arm strong VW,Tenderich G,Sh ipkovaM,et al.Pharm a-cok inetics and b ioavailab ility ofmycophenolic ac id after in-travenous adm in istration and oral adm in istration of myco-phenolate mofetil to heart transp lant rec ip ients[J].TherD rugMon it,2005,27(3):315-21.
• [16]Buchkowsky SS,Partovi N,Ensom MH.C lin ical pharm a-cok inetic mon itoring of itraconazole is warranted in on ly asubset of patients[J].TherD rugMon it,2005,27(3):322-33.
• [17]秦咏九,黄蓓琳,徐新元.紫外分光光度法测定苯妥英钠血药浓度[J].中国临床药学杂志,2004,13(3):174-175.
• [18]任星辉,谈恒山,储小曼.紫外法测定茶碱血药浓度的方法探讨[J].华东医药通讯,1997,8(3):251.
• [19]王淑娟,蔡卫民,郭洪斌.用荧光偏振免疫法和紫外法比较研究茶碱的人体药物动力学[J].中国医院药学杂志,1993,13(6):4901.
• [20]D ick inson L,Rob inson L,Tjia J,et al.S imu ltaneous de-term ination ofH IV protease inh ib itors amprenavir,atazana-vir,ind inavir,lop inavir,nelfinavir,ritonavir and saqu ina-vir in hum an p lasm a by h igh-perform ance liqu id chrom atog-raphy-tandem m ass spectrom etry.J Chrom atogr B AnalytTechnol B iom ed L ife Sc i,2005[Epub ahead of print].
• [21]Stre it F,Sh ipkova M,Arm strong VW,Oellerich M.Vali-dation of a rap id and sensitive liqu id chrom atography-tan-dem m ass spectrom etry m ethod for free and total mycophe-nolic ac id[J].C lin Chem,2004,50(1):152-9.
• [22]W eber LT,Sh ipkovaM,Arm strong VW,et al.Comparisonof the Em it immunoassay w ith HPLC for therapeutic drugmon itoring of mycophenolic ac id in ped iatric renal-trans-p lant rec ip ients on mycophenolate mofetil therapy[J].C linChem,2002,48(3):517-25.
• [23]Herm ida J,Tutor JC.How su itab le are currently used car-bam azep ine immunoassays for quantifying carbam azep ine210,112 epoxide in serum samp les[J].Ther D rugMon it,2003,25(3):384.
• [24]Sh ihab i ZK,O les K,H insdale M.Analysis of the antiep i-leptic drug keppra by cap illary electrophoresis[J].J Chro-m atogr A,2003,1004(1-2):9-12.
• [25]W righton SA,vardonbradon M,R ing B J.The hum an drugm etabolizing cytochrom es P450[J].J pharm acok inet B iop-harm,1996,26:461.
• [26]M artinez FD,G raves PE,Bald in i M,et al.Assoc iationbetween genetic polymorph ism s of theβ2-adrenoceptor andresponse to albuterol in ch ildren w ith and w ithout a h istoryof wheezing[J].J C li n Invest,1997,100:3184.
• [27]E ichelbaum M,Fromm MF,Schwab M.C lin ical aspectsof the MDR1(ABCB1)gene polymorph ism[J].TherD rugMon it,2004,26(2):180-5.
• [28]Ambudkar SV,Dey S,Hrycyna CA,et al.B iochem ical,cellu lar and pharm axological aspects of the mu ltidrug trans-porter[J].Annu Rev Pharm acol Toxical,1999,39:361.
• [29]Owen A,Chand ler B,Back D J.The imp lications of P-gly-coprote in in H IV:friend or foe?[J]Fundam C lin Phar-m acol,2005,19(3):283-96.
• [30]EvansWE,M cLeod HL.Pharm acogenom ic-drug d isposi-tion,drug target,and side effects[J].N Eng J M ed,2003,348(8):538.
• [31]Dah1 ML.Cytochrom e P450 phenotyp ing/genotyp ing inpatients rece iving antipsychotics:usefu l and to prescri-b ing?[J]C lin Pharm acok inet,2002,41(7):453.
• [32]Veenstra DL,H igash i MK,Ph illips KA.Assessing thecost-fectiveness of pharm acogenom ics[J].APPS PharmSc i,2000,2(3):E29.